Sign In
Buy TPST
$1.27
-0.0400 (-3.05%)
At Close: Jun 03, 2026
Tempest Therapeutics Announces Warrant Exercise for Approximately $2 Million in Gross Proceeds
08:00am, Friday, 29'th May 2026
BRISBANE, Calif., May 29, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (the “Company”), a clinical-stage biotechnology company developing a pipeline of advanced CAR-T cell th
Tempest Reports First Quarter 2026 Financial Results and Provides Business Update
04:15pm, Thursday, 14'th May 2026
Announced positive interim data from the ongoing REDEEM-1 Phase 1/2a trial of TPST-2003 in patients with relapsed/refractory multiple myeloma (rrMM)
Tempest Presents Clinical Update at ISCT 2026 Annual Meeting
07:00am, Wednesday, 06'th May 2026
BRISBANE, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”) today presents its most recent clinical data from its lead dual-targeting chimeric antigen
Tempest to Advance Dual-Targeting CAR-T Platform with Clinical Update at ISCT 2026 Annual Meeting
08:00am, Wednesday, 29'th Apr 2026
BRISBANE, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”) will present its most recent clinical data from its lead dual-targeting chimeric antigen
Tempest Announces Key Manufacturing Milestone for TPST-2003 Dual-Targeting CD19/BCMA CAR-T
08:00am, Wednesday, 22'nd Apr 2026
Delivery of TPST-2003 lentiviral vector to Cincinnati Children's Applied Gene and Cell Therapy Center enables manufacturing activities required for pivotal development Tech transfer on track to suppor
Tempest Appoints Andrew Fang, Ph.D., as Head of Business Development to Advance Strategic Partnerships and Global Licensing Efforts
08:00am, Tuesday, 14'th Apr 2026
Adds dedicated business development leadership to support Tempest's strategic priorities Will lead China outreach and cross-border partnership efforts To support ongoing partnering discussions for Pha
New Strong Buy Stocks for April 10th
05:35am, Friday, 10'th Apr 2026
ESCA, GRDN, TPST, ASTE and ECG have been added to the Zacks Rank #1 (Strong Buy) List on April 10th, 2026.
Tempest Reports Year End 2025 Financial Results and Provides Business Update
09:00am, Monday, 30'th Mar 2026
Completed strategic acquisition of dual-targeting CAR-T assets from Factor Bioscience Inc. Named Matt Angel, Ph.D., Chief Executive Officer & President Announced positive interim data from the ongoing
Matthew Angel Purchases 231,482 Shares of Tempest Therapeutics (NASDAQ:TPST) Stock
04:22am, Friday, 27'th Mar 2026
Tempest Therapeutics, Inc. (NASDAQ: TPST - Get Free Report) CEO Matthew Angel acquired 231,482 shares of the company's stock in a transaction on Tuesday, March 24th. The shares were bought at an avera
Tempest Therapeutics (TPST) Projected to Post Quarterly Earnings on Wednesday
01:04am, Wednesday, 25'th Mar 2026
Tempest Therapeutics (NASDAQ: TPST - Get Free Report) is projected to announce its Q4 2025 results before the market opens on Wednesday, April 1st. Analysts expect the company to announce earnings of
Tempest Therapeutics Announces Up To $6 Million Private Placement
08:00am, Monday, 23'rd Mar 2026
BRISBANE, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (the “Company”), a clinical-stage biotechnology company developing a pipeline of advanced CAR-T cell
Head-To-Head Review: Shuttle Pharmaceuticals (NASDAQ:SHPH) versus Tempest Therapeutics (NASDAQ:TPST)
01:00am, Thursday, 19'th Mar 2026
Shuttle Pharmaceuticals (NASDAQ: SHPH - Get Free Report) and Tempest Therapeutics (NASDAQ: TPST - Get Free Report) are both small-cap medical companies, but which is the better business? We will compa
Tempest Announces Partnership for TPST-2003 in Preparation for Planned U.S. Registrational Study in 2026
08:00am, Wednesday, 11'th Mar 2026
Cincinnati Children's Applied Gene and Cell Therapy Center selected to conduct tech transfer, development and IND-enabling manufacturing All activities other than long-term stability testing planned t
Tempest Announces Interim Results from Ongoing REDEEM-1 Trial of TPST-2003, Preparing for Potential U.S. Registrational Study in 2026
07:59am, Wednesday, 25'th Feb 2026
BRISBANE, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”), a clinical-stage biotechnology company developing a pipeline of advanced cell therapy and
Tempest Lays Out Strategic Plan to Advance Recently Acquired Dual-Targeting CAR-T Assets
06:59am, Wednesday, 11'th Feb 2026
Tempest outlines a capital-efficient post-transaction strategy to advance a diversified portfolio of next-generation CAR-T and oncology assets Development approach prioritizes partner-funded and exter
